Investment Rating - The investment rating for the company is "Buy" and the rating has been maintained [4][11]. Core Insights - The company has shown significant growth with a revenue of 2.375 billion yuan in 2025, marking a year-on-year increase of 135.27%. The net profit reached 644 million yuan, a substantial increase from the previous year, indicating the first annual profit for the company [3][11]. - The revenue structure is shifting from a single product focus to a dual-driven model of commercial sales and technology licensing, with drug sales contributing approximately 60.73% and technology licensing accounting for about 38.07% of total revenue [3][11]. - The core product, Acalabrutinib, continues to see rapid commercialization, achieving sales of 1.41 billion yuan, a year-on-year growth of 40.99%. The product's inclusion in medical insurance has significantly improved patient accessibility [3][6][11]. Financial Performance - In 2025, the company reported a net cash flow from operating activities of 84 million yuan, and R&D expenses were 952 million yuan, reflecting a year-on-year increase of 16.82% [3][11]. - The company expects revenues of 2.106 billion yuan, 2.633 billion yuan, and 3.258 billion yuan for 2026, 2027, and 2028 respectively, with a projected net profit of -0.85 million yuan, 116.56 million yuan, and 377.17 million yuan for the same years [11][13]. Product Development - The company has initiated commercialization of Tafasitamab and received NMPA approval for Zolbetuximab, expanding its product matrix and opening new revenue streams [6][10]. - The BCL-2 inhibitor Mesutoclax is progressing through clinical trials and is expected to become a strategic pillar in the hematology sector, with multiple key trials underway [7][11]. - The company is also deepening its layout in the autoimmune disease field, with ongoing clinical developments for Acalabrutinib and TYK2 products across various indications [8][9]. Market Position and Future Outlook - The company is enhancing its commercialization capabilities, which is expected to support revenue growth in the hematology sector and strengthen its long-term global value [6][11]. - The ADC platform is showing significant progress, with multiple candidates in clinical development, providing a continuous growth engine for the company [10][11].

Investment Rating - The investment rating for the company is "Buy" and the rating has been maintained [3][4]. Core Insights - The company has shown significant growth with a total revenue of 2.375 billion yuan in 2025, representing a substantial year-on-year increase of 135.27%. The net profit reached 644 million yuan, marking a turnaround from losses in the previous year [3][11]. - The revenue structure is evolving from a single product focus to a dual-driven model of commercial sales and technology licensing, with drug sales contributing approximately 60.73% and technology licensing accounting for about 38.07% of total revenue [3][11]. - The core product, Aobutinin, continues to experience rapid growth, achieving commercial revenue of 1.41 billion yuan, a year-on-year increase of 40.99%. The internationalization of Aobutinin is also progressing, with approvals in Singapore and submissions in Australia [3][6]. Financial Performance - In 2025, the company achieved a net profit of 644 million yuan, a significant increase from a loss of 10.97 million yuan in the previous year. The operating cash flow turned positive at 84 million yuan [3][11]. - The company expects revenues of 2.106 billion yuan, 2.633 billion yuan, and 3.258 billion yuan for 2026, 2027, and 2028 respectively, with corresponding net profits projected at -0.85 million yuan, 116.56 million yuan, and 377.17 million yuan [11][13]. Product Development and Pipeline - The company has initiated commercialization of Tafasitamab and received NMPA approval for Zolbetuximab, expanding its product matrix and revenue potential [6][10]. - The BCL-2 inhibitor Mesutoclax is progressing through clinical trials and is expected to become a strategic pillar in the hematology field, with multiple key trials underway [7][11]. - The company is also deepening its layout in the autoimmune disease sector, with ongoing clinical developments for Aobutinin and TYK2 products across various indications [8][9]. Market Position and Future Outlook - The company is positioned to leverage its growing commercial capabilities and product pipeline to sustain revenue growth in the hematology sector and expand into solid tumors [6][10]. - The strategic focus on multiple innovative projects, including small molecules and ADCs, is expected to solidify the company's long-term growth trajectory [11][10].

Group 1 - The A-share market for innovative drugs is experiencing significant gains, with companies like Meinohua, Wanbangde, and Lianhuan Pharmaceutical hitting the 10% daily limit, while Ketaobiotech saw a remarkable 20% increase [1] - As of March 21, 2026, the total value of China's innovative drug outbound business development (BD) contracts has reached $57.1 billion, with an upfront payment of $3.3 billion and a total of 53 contracts, representing 41% of the total for 2025, surpassing the entire year of 2024 [1] - Several leading innovative drug companies have confirmed a turning point in profitability, with Hengrui Medicine projecting that nearly 60% of its revenue will come from innovative drugs by 2025, and a growth forecast of over 30% for 2026 [1] Group 2 - The 2026 government work report has significantly elevated the strategic position of the biopharmaceutical industry, placing it alongside integrated circuits and aerospace as a new pillar industry for the nation [1] - Notable companies such as Nuocheng Jianhua, Yunding Xinyao, and Jingtai Holdings are expected to achieve profitability in 2025 [1]

Summary of the Conference Call for 诺诚健华 (Nocera Biopharma) Company Overview - **Company**: 诺诚健华 (Nocera Biopharma) - **Industry**: Biotechnology, focusing on oncology and autoimmune diseases Key Financial Highlights - **2025 Financial Performance**: - Total revenue reached 23.75 billion RMB, a year-on-year increase of 135.3% [2][4] - Net profit of 6.4 billion RMB, marking the first profitable year [2][4] - Cash reserves stood at 78 billion RMB, with positive operating cash flow of 84 million RMB [2][4] - **Sales Growth Expectations for 2026**: - Anticipated drug sales revenue growth of at least 35% [2][6] - Sales expense ratio expected to decrease to 35%-40% [2][23] Product Development and Commercialization - **Key Products**: - **奥布替尼 (Obutinin)**: - Approved for multiple indications including CLL/SLL and MCL, with significant sales growth expected [3][5][23] - NDA submission for ITP expected in H1 2026 [2][11] - **坦西妥单抗 (Tansizumab)**: - Approved for DLBCL, showing superior efficacy in combination therapies [7] - **左来曲替尼 (Zuranolone)**: - Approved for NTRK fusion-positive solid tumors, with promising clinical outcomes [17][20] - **莫斯妥昔单抗 (Mosunetuzumab)**: - Demonstrated high ORR of 84% in MCL, with plans for market submission by 2027 [2][8] Research and Development Pipeline - **Oncology Pipeline**: - Over 10 products in late-stage clinical trials, with multiple approvals expected in the next 2-3 years [3][4] - ADC platform showing promise with B7-H3 ADC (B794) and Claudin-17 ADC (B208) [18][20] - **Autoimmune Disease Pipeline**: - Five products in clinical stages, including ICP-332 and ICP-488 targeting various autoimmune conditions [10][14] - Significant market potential for SLE and other indications, with expected data readouts in 2026 [11][30] Strategic Collaborations - **Partnerships**: - Strategic collaborations with Xenios BioPharma and Premium for asset licensing and development [3][4] - Ongoing discussions for potential new partnerships in 2026 [32] Market Potential and Competitive Landscape - **Market Size**: - The market for Mosunetuzumab in lymphoma and leukemia is projected to exceed 20 billion USD [9] - Significant unmet needs in MDS and AML, with plans for clinical development [25][27] - **Competitive Advantages**: - Unique drug design and mechanisms of action for BCL-2 inhibitors and TYK2 inhibitors [13][14] - Strong safety profiles and efficacy in clinical trials compared to existing therapies [8][26] Future Outlook - **2026 Expectations**: - Continued revenue growth driven by existing products and new launches [34] - Anticipated key milestones in clinical trials and potential new drug applications [34] - Focus on expanding R&D capabilities and exploring innovative treatment options [34] This summary encapsulates the critical insights from the conference call, highlighting the company's financial performance, product pipeline, strategic collaborations, and future outlook in the biotechnology sector.

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 海外監管公告 本公告乃諾誠健華醫藥有限公司（「本公司」）根據香港聯合交易所有限公司證 券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊登之《董事會決議公告》、《2025年年度 報告》、《2025年年度報告摘要》、《2025年度審計報告》、《2025年度非經營性資 金佔用及其他關聯資金往來情況的專項說明》、《2025年度持續督導現場檢查報 告》、《2025年度內部控制評價報告》、《內部控制審計報告》、《2025年度「提質 增效重回報」行動方案的年度評估報告及2026年度「提質增效重回報」行動方案》、 《董事會審核委員會2025年度履職報告》、《董事會關於會計師事務所履職情況 的評估報告》、《董事會審核委員會對會計師事務所履行監督職 ...

Financial Data and Key Metrics Changes - In 2025, total revenue reached RMB 2.37 billion, representing a 135% year-over-year growth [4][15] - Product sales amounted to RMB 1.44 billion, up 43% from the previous year [4][15] - The company achieved a net profit of RMB 644 million, marking its first profitable year [4][15] - Cash position at the end of 2025 was RMB 2.8 billion, supporting ongoing R&D investments [5][16] - R&D expenses were RMB 950 million, reflecting a 16.9% year-over-year growth [16] Business Line Data and Key Metrics Changes - Orelabrutinib received regulatory approval for multiple indications, significantly expanding its commercial space [10][11] - Tafasitamab was approved for DLBCL in mainland China, enhancing the company's oncology portfolio [10][20] - Mesutoclax is being developed for four indications, with ongoing clinical trials showing promising results [11][25] Market Data and Key Metrics Changes - The global partnership strategy yielded a total business development deal value exceeding $2.5 billion in 2025 [5][18] - The company is focusing on expanding its presence in both domestic and international markets, with significant breakthroughs in globalization [18][19] Company Strategy and Development Direction - The company aims to become a global pharmaceutical leader by focusing on oncology and autoimmune diseases [4] - A diversified product portfolio is being developed, transitioning into multiple commercial and late-stage assets [15][17] - The company is investing in innovative platforms such as ADC and molecular glue technologies to enhance its R&D capabilities [16][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over 35% growth in drug sales for 2026, driven by Orelabrutinib and new product launches [17][54] - The company anticipates continued profitability and sustainable growth, supported by a strong pipeline and business development opportunities [55][62] Other Important Information - The company has over 10 phase III registrational studies ongoing, with multiple major products expected to receive regulatory approvals in the next two to three years [14][19] - The first ADC product, ICP-B794, is in the dose escalation stage of phase I trials, showing promising preliminary results [40][46] Q&A Session Summary Question: What is the sales potential for Orelabrutinib in 2026? - Management expects Orelabrutinib to continue growing over 30% due to deeper penetration in CLL and MCL, along with broader hospital coverage [51][53] Question: What is the development plan for ICP-488 overseas? - The company plans to expand indications after the phase III readout and is open to partnerships for global development [57][59] Question: What is the forecast for R&D expenses in 2026? - R&D expenses are expected to grow by around 20% in 2026, focusing on late-stage clinical studies and innovation platforms [61][62] Question: How will ICP-488 position itself against competitors in the psoriasis market? - The company believes its TYK2 inhibitor has a broader potential compared to oral IL-23 therapies, targeting multiple autoimmune diseases [73][75] Question: What are the inclusion criteria for the Orelabrutinib plus Mesutoclax data? - The combination therapy shows promising results in unfit older patients, providing a good treatment option for this population [78]

Financial Data and Key Metrics Changes - In 2025, total revenue reached RMB 2.37 billion, representing a 135% year-over-year growth [4][15] - Product sales reached RMB 1.44 billion, up 43% over the previous year [4][15] - Net profit reached RMB 644 million, marking the company's first year with a profit [4][17] - Cash position at the end of 2025 was RMB 2.8 billion, supporting continued R&D investment [5][17] - R&D expenses were RMB 950 million, reflecting a 16.9% year-over-year growth [17][61] Business Line Data and Key Metrics Changes - Orelabrutinib was approved for first-line treatment of CLL/SLL and included in NRDL, expanding commercial space [5][11] - Tafasitamab was approved for DLBCL in mainland China, enhancing the company's oncology portfolio [5][11] - Zurletrectinib was approved for marketing in China, marking the company's first approved therapy in solid tumors [11][40] Market Data and Key Metrics Changes - The company entered into strategic collaborations with Zenas BioPharma and Freelium, unlocking significant value with total BD deal value exceeding $2.5 billion [5][19] - Globalization is becoming a key growth pillar, with major out-license transactions covering four assets [19] Company Strategy and Development Direction - The company aims to become a global pharmaceutical leader focused on innovative therapies for oncology and autoimmune diseases [4] - A diversified product portfolio is being developed, with multiple commercial and late-stage assets driving future expansion [15][18] - The company is investing in next-generation platforms such as ADC and molecular glue technologies [17][61] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over 35% growth in drug sales for 2026, driven by Orelabrutinib, Tafasitamab, and Zurletrectinib [18][54] - The company achieved profitability ahead of schedule, with expectations for sustainable breakeven in 2026 and 2027 [54][56] Other Important Information - The company has over 10 phase III registrational studies ongoing globally, with multiple major products expected to receive regulatory approvals in the next 2-3 years [14][20] - The pipeline includes innovative therapies for autoimmune diseases, with significant market potential exceeding $150 billion [36][29] Q&A Session Summary Question: What is the sales potential for Orelabrutinib in 2026? - Management expects continued growth over 30% for Orelabrutinib, driven by deeper penetration in CLL and MCL, and broader hospital coverage [52][53] Question: What is the development plan for ICP-488 overseas? - The company plans to expand indications after the phase III readout and is open to partnerships for global development [57][59] Question: What is the forecast for R&D expenses in 2026? - R&D expenses are expected to grow around 20% in 2026, focusing on late-stage clinical studies and innovation platforms [61][62] Question: How will the company position its TYK2 inhibitors amid competition? - The company believes its TYK2 inhibitors have broader potential beyond psoriasis, targeting multiple autoimmune diseases [72][73] Question: What are the inclusion criteria for the Orelabrutinib plus Mesutoclax data? - The combination therapy targets unfit older patients, achieving a 65% MRD-negative rate, demonstrating good results in this population [79]

Core Insights - InnoCare Pharma achieved its first full year of profitability in 2025, marking a significant milestone in its 10th anniversary, with revenue growth driven by strategic business development and enhanced market penetration of core products [2][9] - The company secured two new drug application approvals and accelerated its globalization strategy through transformative licensing agreements, enhancing its global influence and financial performance [4][5] Financial Highlights - Revenue grew 135.3% year-on-year to RMB 2,375 million in 2025, primarily due to robust commercial growth and strategic business development deals [9] - Profit reached RMB 644 million, achieving profitability for the first time, attributed to significant commercialization growth and global out-licensing deals [9] - Gross Profit Margin increased by 5.7 percentage points to 92% [9] - Research and Development Investment rose by 16.9% to RMB 952 million, reflecting advancements in multiple Phase III trials and increased investments in new technology platforms [9] - Cash and Related Accounts Balance stood at approximately RMB 7.8 billion as of December 31, 2025, with positive operating cash flow for the first time [9] Globalization Strategy - InnoCare accelerated its globalization strategy in 2025, unlocking global value through two out-licensing deals, significantly enhancing its global presence [4][5] - A licensing agreement with Zenas for its autoimmune disease pipeline, including orelabrutinib, has a total deal value exceeding US$2 billion, setting a record for small molecule autoimmune out-licensing in China [5][6] - Another licensing agreement with Prolium aims to further expand InnoCare's global presence, with ongoing clinical studies expected to advance in 2026 [7] Hemato-Oncology Franchise - InnoCare made significant progress in building a leading hemato-oncology franchise, with orelabrutinib approved for first-line chronic lymphocytic leukemia/small lymphocytic lymphoma and tafasitamab becoming the first CD19 antibody approved for relapsed or refractory diffuse large B-cell lymphoma in China [11][16] - Drug sales in this segment increased by 43.4% to RMB 1,442 million in 2025 [11] - Mesutoclax (ICP-248), the first BCL2 inhibitor granted Breakthrough Therapy Designation in China, continues to advance across multiple indications, supporting near-term revenue growth [12][19] Autoimmune Disease Pipeline - The global market for autoimmune disease therapeutics is projected to reach $185 billion by 2029, with InnoCare focusing on B-cell and T-cell pathways to develop first-in-class treatments [22] - Orelabrutinib is positioned to address significant unmet medical needs in immune thrombocytopenia and systemic lupus erythematosus, with pivotal studies showing promising results [23][24] - The company is collaborating with Zenas to accelerate global Phase III clinical trials for orelabrutinib in multiple sclerosis, tapping into a market exceeding US$12 billion [25] Solid Tumor Development - InnoCare is building a diversified portfolio for solid tumors, combining targeted small molecules with next-generation antibody-drug conjugates (ADCs) [39] - Zurletrectinib (ICP-723), a next-generation TRK inhibitor, has shown outstanding efficacy in clinical trials for NTRK gene fusion-positive tumors, with an overall response rate of 89.1% [40][41] - The company is advancing multiple ADC candidates, including ICP-B794 and ICP-B208, targeting solid tumors with promising preclinical results [45][47]

公司秘书指本公司的公司秘书。 董事指董事会成员。 本集团指于有关期间，本公司及其附属公司和联营公司；或 若文义另有所指，于本公司成为其现时附属公司和联营公司 的控股公司前期间，本公司现时附属公司和联营公司；或其 现时附属公司和联营公司或其前身（视乎具体情况）所营运 的业务。 香港上市规则指《香港联合交易所有限公司证券上市规则》（经 不时修订）。 科创板适用规则指因本公司股票在上海证券交易所科创板上市而适 用于本公司的中国境内法律、法规、规范性文件。 提名委员会职权范围 定义 1. 就本职权范围（「职权范围」）而言： 董事会指本公司的董事会。 财务总监指董事会不时委任负责财务管理的本公司高级行政 人员。 提名委员会指董事会根据本职权范围第2条通过的决议案而设 立的提名委员会。 高级管理层指主席、行政总裁、首席财务官、首席技术官及 本公司任何其他行政人员，而其薪酬待遇或建议薪酬待遇较 董事会委任的任何行政人员为优厚；及薪酬委员会厘定的本 公司任何其他雇员。 股东指本公司股东。 联交所指香港联合交易所有限公司。 成立 – 1 – 2. 提名委员会于二零一九年九月二十七日根据董事会所通过的决 议案成立。 成员 会议次 ...